Jacqui Shea, President and CEO, highlighted that Inovio remains on track to submit its BLA for INO-3107, stating, "our goal is to begin rolling submission in mid-2025, complete the submission in the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CEO Jacqueline Shea highlighted, “we have achieved our primary objective for this year, which is completing the rolling submission of our BLA for INO-3107. This represents a milestone in our work to ...
PLYMOUTH MEETING, Pa., Nov. 13, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from ...
Company will request Rolling Submission and Priority Review of its Biological License Application (BLA) by U.S. Food and Drug Administration (FDA) to expedite review process Accelerating ...
Inovio Pharmaceuticals is highly dependent on the regulatory outcome for INO-3107, its DNA-based therapeutic for recurrent respiratory papillomatosis (RRP). The FDA accepted the BLA for INO-3107 but ...
On Wednesday, 25 February 2026, Inovio Pharmaceuticals (NASDAQ:INO) presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. The discussion, led by CEO Jackie Shea and CMO Mike ...
The company reiterated its plan to submit the BLA for INO-3107 under the FDA's rolling submission process in mid-2025, aiming for FDA acceptance of the filing by year-end and a potential PDUFA date in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results